Guardian of genome on the tract: Wild type p53-mdm2 complex inhibition in healing the breast cancer

被引:5
|
作者
Janani, S. K. [1 ]
Dhanabal, S. P. [2 ]
Sureshkumar, R. [1 ]
Surya, Nikitha Upadhyayula Sai [1 ]
Chenmala, Karthika [1 ]
机构
[1] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut, Nilgiris, Tamil Nadu, India
[2] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmacognosy & Phytopharm, Nilgiris, Tamil Nadu, India
关键词
Breast cancer; P53; Mdm2; Apoptosis; Anti-angiogenic activity; Anti-metastatic activity; PROTEIN STABILITY; DOWN-REGULATION; P53; PATHWAY; APOPTOSIS; CELLS; MDM2; ROLES; DEGRADATION; PROGRESSION; ACTIVATION;
D O I
10.1016/j.gene.2021.145616
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Breast cancer acts as an assassin among women. According to WHO (world health organisation), about 6, 27,000 deaths have occurred in 2018 due to breast cancer. Since, the evolution of cancer involves many complicated pathway, in this article we have decided to focus on wild type p53. P53 is also called as tumor suppressor gene. As the name suggest, p53 is a real guardian of genome, if it is not mutated or subjected to degradation. It can perform a wide range of activities during cancer progression. It either stimulates or inhibits the genes or proteins that are responsible for cell cycle arrest, apoptosis, anti-angiogenic activity and anti-metastatic activity. At times, the p53 will be unable to produce its action due to various reasons like mutation or degradation by other proteins or degrading ligases. Since, we are focusing on wild type p53, it will be inhibited occasionally by mdm2 resulting in proteosomal degradation of p53. However, this condition can be prevented by possible treatment regimen. With the above points in mind, we have focused on p53 activation, complex formation between p53 and mdm2, and inhibition of the complex in order to free p53 and allow them to perform their action for rehabilitation of cancer. Furthermore, we have also discussed pathways involved in eradicating cancer through p53 activation. By considering the following aspects, hope that p53 can be considered for management of breast cancer.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] A Left-Handed Solution to Peptide Inhibition of the p53-MDM2 Interaction
    Liu, Min
    Pazgier, Marzena
    Li, Changqing
    Yuan, Weirong
    Li, Chong
    Lu, Wuyuan
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2010, 49 (21) : 3649 - 3652
  • [2] KLF11 promotes the proliferation of breast cancer cells by inhibiting p53-MDM2 signaling
    Hou, Zhi-Han
    Tao, Min
    Dong, Jiang
    Qiu, Hong-Mei
    Li, Fan
    Bai, Xiao-Yan
    CELLULAR SIGNALLING, 2024, 120
  • [3] Effect of Nutlin-3a on stability of p53-MDM2 complex
    Zhou, Han
    Geng, Yi-Zhao
    Yan, Shi-Wei
    ACTA PHYSICA SINICA, 2023, 72 (06)
  • [4] Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis
    Lai, Chunwei W.
    Xie, Cindy
    Raufman, Jean-Pierre
    Xie, Guofeng
    CANCERS, 2022, 14 (01)
  • [5] Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
    On, Jasmin Linh
    Ghaderi, Sahel
    Rittmann, Carina
    Hoffmann, Greta
    Gier, Franziska
    Woloschin, Vitalij
    Tu, Jia-Wey
    Bhatia, Sanil
    Kulik, Andrea
    Niederacher, Dieter
    Neubauer, Hans
    Kurz, Thomas
    Fehm, Tanja
    Esser, Knud
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (03)
  • [6] In Vitro Characterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Cancer Cell Lines
    Al-Ghabkari, Abdulhameed
    Narendran, Aru
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2019, 34 (04) : 252 - 257
  • [7] Targeting the MDM2-MDM4 interaction interface reveals an otherwise therapeutically active wild-type p53 in colorectal cancer
    Valentini, Sonia
    Mele, Giada
    Attili, Marika
    Assenza, Maria Rita
    Saccoccia, Fulvio
    Sardina, Francesca
    Rinaldo, Cinzia
    Massari, Roberto
    Tirelli, Nicola
    Pontecorvi, Alfredo
    Moretti, Fabiola
    MOLECULAR ONCOLOGY, 2025,
  • [8] Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy
    Das, Manasi
    Dilnawaz, Fahima
    Sahoo, Sanjeeb K.
    NANOMEDICINE, 2011, 6 (03) : 489 - 507
  • [9] Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions
    Munisamy, Murali
    Mukherjee, Nayonika
    Thomas, Levin
    Pham, Amy Trinh
    Shakeri, Arash
    Zhao, Yusheng
    Kolesar, Jill
    Rao, Praveen P. N.
    Rangnekar, Vivek M.
    Rao, Mahadev
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (12): : 5762 - +
  • [10] Actinomycin D synergistically enhances the cytotoxicity of CDDP on KB cells by activating P53 via decreasing P53-MDM2 complex
    Wang, Lin
    Pang, Xiao-Cong
    Yu, Zi-Ru
    Yang, Sheng-Qian
    Liu, Ai-Lin
    Wang, Jin-Hua
    Du, Guan-Hua
    JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH, 2017, 19 (06) : 630 - 643